[REVISION HISTORY]

Novo Nordisk pivots strategy to counter patent cliff

Updated 25 times since CLSTR started tracking revisions of this situation.

What changed

2026-10-21 20:36 UTC → 2026-10-25 12:34 UTC · added ~~removed~~

Novo Nordisk is implementing a strategic reset to address long-term growth concerns and the looming patent expiration of semaglutide in the early 2030s. To diversify its portfolio and counter competition from Eli Lilly, the company is prioritizing next-generation obesity treatments, such as the CagriSema combination therapy, and expanding its oral medication pipeline. The company has successfully transitioned toward oral therapies, with the Wegovy pill capturing 90% of the oral obesity market in the U.S. and launching in ~~Germany as the first EU commercialization of the format.~~ Germany. To support this, Novo Nordisk aims to increase oral GLP-1 production tenfold to serve 15 million patients by 2030. ~~Clinical efforts also include~~ Real-world data from the OCTANE study suggests oral semaglutide is a ~~Phase 3 trial~~ viable alternative for patients switching from injectables, maintaining weight loss and high satisfaction. To bolster its pipeline, Novo Nordisk has entered several strategic licensing agreements. This includes a ~~lower-dose Wegovy pill~~ deal worth up to ~~meet demand among self-paying patients.~~ $1.33 billion with Swedish biotech Nanexa to utilize PharmaShell technology, which aims to extend dosing intervals from weekly to monthly or quarterly injections. Additionally, the company secured global rights for HRS-1596, a GLP-1 and GIP dual agonist from China’s Hengrui Pharma, which could potentially be administered as a once-weekly oral pill. Despite clinical successes, ~~including positive results in pediatric~~ such as the STEP Young study showing semaglutide significantly reduces obesity ~~trials,~~ in children aged 6 to 12, the company faces ~~significant financial scrutiny. Analysts from Deutsche Bank and Morgan Stanley~~ intense competition. While CagriSema has shown results outperforming Eli Lilly’s Tirzepatide in certain metrics, Novo Nordisk’s shares have ~~issued downgrades, citing concerns~~ declined by approximately one-third over ~~stagnant revenue, dependency on semaglutide, and potential profit declines~~ the past year due to U.S. pricing pressures. During a recent Capital Markets Day, CEO Mike Doustdar outlined a roadmap to launch over five multi-blockbuster drugs by 2030, targeting DKK 150 billion in pipeline sales by 2035. However, investor concerns regarding margin stability the rise of Mounjaro and Zepbound, as well as the ~~competitive landscape led to a notable decline~~ emergence of cheaper generics in ~~share price.~~ markets like India and Canada.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.